Research analysts who have asked questions during Intercure earnings calls.
Recent press releases and 8-K filings for INCR.
InterCure Signs Strategic Investment and Collaboration Agreements with Cannasoul
INCR
M&A
New Projects/Investments
- InterCure Ltd. announced on November 3, 2025, that it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd..
- The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis, with an exclusive path to increase its holdings to 51% within two years.
- The Collaboration Agreement formalizes a partnership for research, development, and commercialization of evidence-based cannabis therapeutics.
- Prof. Dedi Meiri, Founder of Cannasoul, is expected to be appointed as the Chairperson of InterCure's Scientific Advisory Board to integrate Cannasoul's advanced analytics and research capabilities into InterCure's pharmaceutical platform.
Nov 3, 2025, 1:40 PM
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements
INCR
New Projects/Investments
M&A
- InterCure Ltd. has entered into a Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd., a globally recognized pioneer in cannabis research and analytics.
- The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase its holdings to 51% within two years.
- The Collaboration Agreement formalizes a partnership for the research, development, and commercialization of evidence-based cannabis therapeutics.
- Prof. Dedi Meiri, Founder of Cannasoul, is expected to be appointed as the Chairperson of InterCure’s Scientific Advisory Board.
- These agreements coincide with reports that the Trump administration is exploring cannabis rescheduling, which could create unprecedented opportunities for international operators like InterCure.
Nov 3, 2025, 1:30 PM
InterCure Reports First Half 2025 Results
INCR
Earnings
M&A
- InterCure reported NIS 130 million in revenue for the first half of 2025, an increase of 3% compared to the first half of 2024.
- The company achieved NIS 12.6 million in Adjusted EBITDA and generated NIS 12 million in positive operating cash flow during the first half of 2025.
- InterCure recorded a net loss of NIS 1.8 million for the first half of 2025, and had NIS 54 million in cash on hand as of June 30, 2025.
- The company signed an agreement in September 2025 to acquire Botanico Ltd. (ISHI), a strategic move expected to enhance access to premium U.S. genetics and international market opportunities, while also monitoring U.S. cannabis rescheduling developments.
Oct 8, 2025, 1:03 PM
InterCure Reports First Half 2025 Results
INCR
Earnings
M&A
Revenue Acceleration/Inflection
- InterCure Ltd. reported NIS 130 million in revenue for the first half of 2025, marking a 3% increase compared to the first half of 2024.
- The company achieved NIS 12 million in positive operating cash flow, a significant improvement from negative NIS 43 million in the first half of 2024.
- Net loss for the period was NIS 1.8 million, compared to near break-even in the first half of 2024, with Adjusted EBITDA reaching NIS 12.6 million.
- InterCure received NIS 81 million in compensation advances from Israeli authorities for war-related damages, out of a total submitted claim of NIS 251 million.
- In September 2025, the company signed an agreement to acquire Botanico Ltd. (ISHI), a strategic move to enhance access to U.S. genetics and international market opportunities.
Oct 8, 2025, 12:50 PM
InterCure Announces Strategic Acquisition of ISHI
INCR
M&A
New Projects/Investments
Management Change
- InterCure Ltd. announced the strategic acquisition of Botanico Ltd., also known as ISHI, a premium medical cannabis technology and brand company, on September 19, 2025.
- This acquisition provides InterCure with immediate access to advanced cultivation technologies and established partnerships with leading American cannabis operators, including The Flowery, positioning InterCure to capitalize on the evolving U.S. cannabis market.
- The transaction is structured as a two-phase acquisition of 100% of ISHI, with the initial closing expected in Q1 2026, subject to regulatory approvals.
- The total consideration for the acquisition is 4,513,663 ordinary shares and 410,599 options of InterCure, representing approximately 10% of InterCure's outstanding shares on a fully diluted basis prior to the initial closing.
- ISHI founders Omer Layani (CEO) and Dor Hershkovitz (COO) will join InterCure's leadership team as part of the acquisition.
Sep 19, 2025, 12:49 PM
Quarterly earnings call transcripts for Intercure.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more